Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer : A prospective study
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd..
BACKGROUND: CDK4/6 inhibitors in combination with traditional endocrine therapy (ET) have become the recommended first-line therapy for HR-positive/HER2-negative metastatic breast cancer (MBC). The aim of this prospective study was to evaluate the relationship between HER2-low expression and clinical outcomes in HR-positive/HER2-negative MBC patients receiving ET with or without CDK4/6 inhibitors.
METHODS: Between April 2016 and November 2019, 233 women with HR-positive/HER2-negative MBC who received ET with or without CDK4/6 inhibitors were enrolled into the study. The primary endpoint was progression-free survival (PFS). Statistical analysis included descriptive statistics, Kaplan-Meier curves, and Cox proportional hazards models.
RESULTS: HER2-low and HER2-zero subgroups in the CDK4/6 inhibitor plus ET cohort showed no significant difference in the median PFS (10.9 vs. 8.0 months; hazard ratio: 0.92; 95% confidence interval [CI]: 0.64-1. 30; p = 0.65), while HER2-low subgroup showed a significantly shorter median PFS compared to the HER2-zero subgroup in the ET alone cohort (5.6 vs. 17.0 months; hazard ratio: 2.82; 95% CI: 1.34-5.93; p = 0.0044). Moreover, the objective response rate was significantly lower in the HER2-low subgroup than the HER2-zero subgroup in the ET alone cohort (10.5% vs. 40.0%, p = 0.047). Lastly, no significant difference was observed in the overall survival between the HER2-low and HER2-zero subgroups in both cohorts.
CONCLUSION: This study suggested that HER2-low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR-positive/HER2-negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR-positive MBC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Thoracic cancer - 15(2024), 12 vom: 11. Apr., Seite 965-973 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wu, Yun [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.04.2024 Date Revised 28.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/1759-7714.15282 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369702174 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369702174 | ||
003 | DE-627 | ||
005 | 20240428231943.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/1759-7714.15282 |2 doi | |
028 | 5 | 2 | |a pubmed24n1391.xml |
035 | |a (DE-627)NLM369702174 | ||
035 | |a (NLM)38480513 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wu, Yun |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer |b A prospective study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.04.2024 | ||
500 | |a Date Revised 28.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd. | ||
520 | |a BACKGROUND: CDK4/6 inhibitors in combination with traditional endocrine therapy (ET) have become the recommended first-line therapy for HR-positive/HER2-negative metastatic breast cancer (MBC). The aim of this prospective study was to evaluate the relationship between HER2-low expression and clinical outcomes in HR-positive/HER2-negative MBC patients receiving ET with or without CDK4/6 inhibitors | ||
520 | |a METHODS: Between April 2016 and November 2019, 233 women with HR-positive/HER2-negative MBC who received ET with or without CDK4/6 inhibitors were enrolled into the study. The primary endpoint was progression-free survival (PFS). Statistical analysis included descriptive statistics, Kaplan-Meier curves, and Cox proportional hazards models | ||
520 | |a RESULTS: HER2-low and HER2-zero subgroups in the CDK4/6 inhibitor plus ET cohort showed no significant difference in the median PFS (10.9 vs. 8.0 months; hazard ratio: 0.92; 95% confidence interval [CI]: 0.64-1. 30; p = 0.65), while HER2-low subgroup showed a significantly shorter median PFS compared to the HER2-zero subgroup in the ET alone cohort (5.6 vs. 17.0 months; hazard ratio: 2.82; 95% CI: 1.34-5.93; p = 0.0044). Moreover, the objective response rate was significantly lower in the HER2-low subgroup than the HER2-zero subgroup in the ET alone cohort (10.5% vs. 40.0%, p = 0.047). Lastly, no significant difference was observed in the overall survival between the HER2-low and HER2-zero subgroups in both cohorts | ||
520 | |a CONCLUSION: This study suggested that HER2-low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR-positive/HER2-negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR-positive MBC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a CDK4/6 inhibitors | |
650 | 4 | |a HER2‐low | |
650 | 4 | |a endocrine therapy | |
650 | 4 | |a metastatic breast cancer | |
650 | 4 | |a prospective analysis | |
650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a ERBB2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Cyclin-Dependent Kinase 4 |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
650 | 7 | |a Cyclin-Dependent Kinase 6 |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a CDK4 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
650 | 7 | |a CDK6 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
700 | 1 | |a Mo, Hongnan |e verfasserin |4 aut | |
700 | 1 | |a Xu, Hangcheng |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yan |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jiayu |e verfasserin |4 aut | |
700 | 1 | |a Ma, Fei |e verfasserin |4 aut | |
700 | 1 | |a Xu, Binghe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 15(2024), 12 vom: 11. Apr., Seite 965-973 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2024 |g number:12 |g day:11 |g month:04 |g pages:965-973 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.15282 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2024 |e 12 |b 11 |c 04 |h 965-973 |